FDA Phases Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs
Key Insights
FDA has announced plans to eliminate mandatory animal testing requirements for monoclonal antibodies (search) and certain other pharmaceutical products, marking a significant shift in drug development regulations.
The announcement comes amid broader regulatory changes at FDA, including recent approvals of cancer treatments such as nivolumab with ipilimumab for hepatocellular carcinoma (search) and durvalumab for muscle invasive bladder cancer (search).
HHS Secretary Robert F. Kennedy Jr. framed these changes as part of a "generational opportunity" to reform the regulatory agency, while the department undergoes significant restructuring with personnel cuts and division consolidations.
The U.S. Food and Drug Administration (FDA) has announced plans to phase out animal testing requirements for monoclonal antibodies (search) and other pharmaceutical products, signaling a major shift in the drug development and approval process.
This regulatory change comes as part of broader reforms within the agency and the Department of Health and Human Services (HHS), which is undergoing significant restructuring including personnel reductions, function centralizations, and division consolidations.
Regulatory Shift Away from Animal Testing
The move to eliminate mandatory animal testing for monoclonal antibodies (search) represents a substantial evolution in the FDA's approach to ensuring drug safety and efficacy. Monoclonal antibodies, which form the basis of many modern targeted therapies, have traditionally required extensive animal testing before advancing to human trials.
HHS Secretary Robert F. Kennedy Jr., addressing FDA employees, characterized the current administration's tenure as a "generational opportunity to make the regulatory agency live up to its foundational ideals" and to emerge from what he described as the "deep state." This language signals the administration's intent to fundamentally reshape the agency's operations and regulatory framework.
Recent FDA Oncology Approvals
Amid these regulatory changes, the FDA continues its work evaluating and approving new cancer therapies:
On April 11, the agency approved the combination of nivolumab (Opdivo) with ipilimumab (Yervoy) for first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (search). This immunotherapy combination provides a new option for patients with this aggressive form of liver cancer.
The FDA also granted full approval for Vitrakvi (larotrectinib), a first-in-class TRK inhibitor (search) for adult and pediatric patients with solid tumors harboring neurotrophic receptor tyrosine kinase (search) gene fusions. The approval applies to tumors without known acquired resistance mutations that are either metastatic, where surgical resection would likely result in severe morbidity, or that have progressed following treatment when no satisfactory alternative treatments exist.
Additionally, the agency approved Biocon Biologics Ltd (search)'s Jobevne (search) (bevacizumab-nwgd (search)), a biosimilar to Avastin (bevacizumab). This recombinant humanized monoclonal antibody is used to treat several different types of cancer and represents continued expansion of biosimilar options in oncology.
In the bladder cancer space, the FDA approved AstraZeneca's durvalumab (Imfinzi) with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment following radical cystectomy for adults with muscle invasive bladder cancer (search).
Legal Challenges to FDA Authority
While the FDA implements these changes, its regulatory authority faces legal challenges in other areas. A federal judge recently ruled that the FDA lacks statutory authority to regulate laboratory developed tests (LDTs), finding in favor of plaintiffs in consolidated lawsuits brought by the American Clinical Laboratory Association, Association for Molecular Pathology, and others. The American Society for Clinical Pathology had submitted an amicus brief supporting the plaintiffs.
This ruling represents a significant limitation on the FDA's oversight capabilities in the rapidly evolving field of diagnostic testing, potentially affecting how new tests are developed and brought to market.
HHS Restructuring
The changes at FDA are occurring within the context of broader restructuring at HHS. The department has announced sweeping revisions to its organization, including personnel cuts, centralization of functions, and consolidation of divisions. These structural changes may have far-reaching implications for how health and pharmaceutical regulations are developed and implemented in the coming years.
The elimination of animal testing requirements for monoclonal antibodies (search) and other drugs marks a significant shift in pharmaceutical development processes. As alternative testing methods continue to advance, this change could potentially accelerate the development timeline for new therapies while addressing longstanding ethical concerns about animal testing in drug development.